See more : Kongsberg Gruppen ASA (KOG.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Enzolytics Inc. (ENZC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enzolytics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Autoliv, Inc. (0MI0.L) Income Statement Analysis – Financial Results
- Grupo Radio Centro, S.A.B. de C.V. (RCENTROA.MX) Income Statement Analysis – Financial Results
- China New Energy Group Co. (CNER) Income Statement Analysis – Financial Results
- Chang Jia M&E Engineering Corp. (4550.TWO) Income Statement Analysis – Financial Results
- Sangamo Therapeutics, Inc. (0R1D.L) Income Statement Analysis – Financial Results
Enzolytics Inc. (ENZC)
About Enzolytics Inc.
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.80K | 0.00 | 200.00K | 0.00 | 0.00 | 5.00K | 190.00K | 0.00 | 0.00 | 36.97K | 14.71K | 5.69K | 0.00 |
| Cost of Revenue | 22.09K | 22.09K | 16.96K | 16.96K | 16.96K | 16.81K | 741.20K | 18.75K | 19.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 30.71K | -22.09K | 183.04K | -16.96K | -16.96K | -11.81K | -551.20K | -18.75K | -19.22K | 36.97K | 14.71K | 5.69K | 0.00 |
| Gross Profit Ratio | 58.16% | 0.00% | 91.52% | 0.00% | 0.00% | -236.20% | -290.10% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 171.61K | 567.87K | 116.75K | 501.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.90M | 936.82K | 394.12K | 40.20K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.01M | 2.31M | 1.47M | 2.78M | 645.41K | 1.69M | 264.81K | 45.29K | 5.02M | 2.90M | 936.82K | 394.12K | 40.20K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.29M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.18M | 2.88M | 1.59M | 3.29M | 645.41K | 1.69M | 264.81K | 45.29K | 5.02M | 2.91M | 950.12K | 403.00K | 43.18K |
| Cost & Expenses | 2.20M | 2.90M | 1.61M | 3.30M | 662.37K | 1.71M | 1.01M | 64.04K | 5.04M | 2.91M | 950.12K | 403.00K | 43.18K |
| Interest Income | 2.00 | 60.00 | 91.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 27.72K | 37.32K | 37.33K | 177.30K | 118.82K | 50.99K | 61.73K | 21.92K | 24.62K | 68.95K | 34.38K | 28.64K | 21.64K |
| Depreciation & Amortization | 22.09K | 22.09K | 20.44K | 16.96K | 16.96K | 16.81K | 322.99K | 18.75K | 19.22K | 12.38K | 13.30K | 8.87K | 2.98K |
| EBITDA | -2.12M | -2.88M | -611.72K | -3.29M | 1.06M | -1.69M | 327.44K | -45.29K | -5.02M | -7.43M | -922.12K | -388.44K | 316.60K |
| EBITDA Ratio | -4,019.30% | 0.00% | -695.19% | 0.00% | 0.00% | -33,798.60% | -259.48% | 0.00% | 0.00% | -16,649.25% | -6,269.48% | -6,830.26% | 0.00% |
| Operating Income | -2.15M | -2.90M | -1.41M | -3.30M | -662.37K | -1.71M | -816.01K | -64.04K | -5.04M | -2.88M | -935.41K | -397.31K | -43.18K |
| Operating Income Ratio | -4,070.01% | 0.00% | -705.41% | 0.00% | 0.00% | -34,134.80% | -429.48% | 0.00% | 0.00% | -7,777.15% | -6,359.89% | -6,986.30% | 0.00% |
| Total Other Income/Expenses | -28.03K | -37.26K | 741.33K | -177.30K | 1.58M | -50.99K | 758.73K | -489.33K | -24.62K | -4.64M | -34.38K | -28.64K | -356.80K |
| Income Before Tax | -2.18M | -2.94M | -669.49K | -3.48M | 920.43K | -1.76M | -57.28K | -553.37K | -5.07M | -7.51M | -969.79K | 0.00 | -399.98K |
| Income Before Tax Ratio | -4,123.10% | 0.00% | -334.74% | 0.00% | 0.00% | -35,154.52% | -30.15% | 0.00% | 0.00% | -20,325.46% | -6,593.61% | 0.00% | 0.00% |
| Income Tax Expense | 2.00 | 2.00 | -2.00 | -4.00 | -4.00 | 0.00 | -4.00 | -3.78K | -19.28K | -3.22M | 0.00 | 28.64K | 378.44K |
| Net Income | -2.18M | -2.94M | -669.49K | -3.48M | 920.43K | -1.76M | -57.28K | -549.59K | -5.05M | -7.51M | -969.79K | -425.95K | -421.62K |
| Net Income Ratio | -4,123.10% | 0.00% | -334.74% | 0.00% | 0.00% | -35,154.52% | -30.15% | 0.00% | 0.00% | -20,325.46% | -6,593.61% | -7,489.85% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.04 | -541.66 | -256.63 | -118.91 | -155.29 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.04 | -541.66 | -256.63 | -118.91 | -155.29 |
| Weighted Avg Shares Out | 2.93B | 2.82B | 2.80B | 959.33M | 959.33M | 391.52M | 171.67M | 110.79M | 114.79M | 13.87K | 3.78K | 3.58K | 2.72K |
| Weighted Avg Shares Out (Dil) | 2.93B | 2.82B | 2.80B | 959.33M | 959.33M | 391.52M | 171.67M | 110.79M | 114.79M | 13.87K | 3.78K | 3.58K | 2.72K |
List Of Penny Stocks to Buy This Week? 7 to Watch Right Now
Which penny stocks are on your list as July gets off to a great start? The post List Of Penny Stocks to Buy This Week?
Best Biotech Penny Stocks In Summer 2021? 7 For Your Watchlist
Are these the best biotech penny stocks to watch right now? The post Best Biotech Penny Stocks In Summer 2021?
What Penny Stocks to Buy Today? 7 Small-Caps to Watch Right Now
Which penny stocks are on your watchlist today? Here's 7 for some inspiration The post What Penny Stocks to Buy Today?
Enzolytics Announces Its Progress Toward Completion of Clinical Trials for Its Anti-HIV ITV-1 Therapeutic and Plans for Its Distribution Throughout Europe
COLLEGE STATION, TX / ACCESSWIRE / June 14, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has concluded definitive plans to advance its previously tested ITV-1 anti-HIV therapeutic to clinical trials and distribution throughout Europe. Completion of these steps will establish...
Top Biotech Penny Stocks to Buy? Check These Small-Caps Out
Which biotech penny stocks are on your watchlist as Covid comes to an end? The post Top Biotech Penny Stocks to Buy?
Enzolytics Announces A Comprehensive Therapeutic Protocol For Production Of Monoclonal Antibodies To Address Ongoing And Future Pandemics
COLLEGE STATION, TX / ACCESSWIRE / June 7, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced a coherent protocol that it intends to execute to meet the Company's objective of producing a therapeutic cure for HIV as well as...
4 Hot Penny Stocks to Watch in 2021, Are They on Your Watchlist?
Making a penny stocks watchlist in 2021? Check these 4 small-caps out The post 4 Hot Penny Stocks to Watch in 2021, Are They on Your Watchlist?
Enzolytics Announces the Discovery of Conserved, Immutable Target Sites on HTLV-1 and Plans To Commence Production of Monoclonal Antibodies Targeting These Sites
COLLEGE STATION, TX / ACCESSWIRE / May 26, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") today announced it has identified conserved, expectedly immutable sites on the HTLV-1 virus against which it will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs). There...
Coronavirus Targeted Epitopes Claimed in Enzolytics' Pending Patent Applications are Verified as Fully Conserved in the UK, Brazil and South African Variants of the Coronavirus (SARS-COV-2)
COLLEGE STATION, TX / ACCESSWIRE / April 5, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (or the "Company"). In a significant development, recent findings have revealed that the monoclonal antibodies being produced by the Company against targeted sites on the Coronavirus...
Enzolytics Announces the Discovery and Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus
Production of monoclonal antibodies targeting these sites is in process. U.S. patent protection has been filed claiming these sites.
Source: https://incomestatements.info
Category: Stock Reports